BR112022024533A2 - Formulação compreendendo daprodustat - Google Patents

Formulação compreendendo daprodustat

Info

Publication number
BR112022024533A2
BR112022024533A2 BR112022024533A BR112022024533A BR112022024533A2 BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2 BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2
Authority
BR
Brazil
Prior art keywords
daprodustat
formulation including
immediate release
release tablet
aspects
Prior art date
Application number
BR112022024533A
Other languages
English (en)
Portuguese (pt)
Inventor
Chattoraj Sayantan
Ryan Croy Scott
Anderson Mcleod James
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112022024533A2 publication Critical patent/BR112022024533A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112022024533A 2020-06-19 2021-06-17 Formulação compreendendo daprodustat BR112022024533A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063041403P 2020-06-19 2020-06-19
US202063043292P 2020-06-24 2020-06-24
PCT/EP2021/066386 WO2021255159A1 (en) 2020-06-19 2021-06-17 Formulation comprising daprodustat

Publications (1)

Publication Number Publication Date
BR112022024533A2 true BR112022024533A2 (pt) 2022-12-27

Family

ID=76730508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024533A BR112022024533A2 (pt) 2020-06-19 2021-06-17 Formulação compreendendo daprodustat

Country Status (7)

Country Link
US (1) US20230225977A1 (cg-RX-API-DMAC7.html)
EP (1) EP4167967A1 (cg-RX-API-DMAC7.html)
JP (1) JP7797425B2 (cg-RX-API-DMAC7.html)
CN (1) CN115697307A (cg-RX-API-DMAC7.html)
BR (1) BR112022024533A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180509A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021255159A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240228443A1 (en) * 2021-06-18 2024-07-11 Glaxosmithkline Intellectual Property (No.2) Limited Novel manufacturing method of daprodustat and precursors thereof
WO2024257063A1 (en) * 2023-06-16 2024-12-19 Glenmark Life Sciences Limited Solid dispersion of daprodustat and a process for the preparation thereof
KR20260061246A (ko) * 2023-10-24 2026-05-06 카인드 파마슈티컬 저산소증 유도인자-프로릴히드록시라제 억제제를 함유하는 장시간 작용형 경구 의약품 및 그 사용

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
NZ735973A (en) * 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
TWI804919B (zh) * 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
RU2736941C2 (ru) * 2015-12-02 2020-11-23 Мерк Шарп энд Доум Корп. Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
PH12018000227B1 (en) * 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
AU2018330994A1 (en) * 2017-09-15 2020-04-16 GlaxoSmithKline Intellectual Property (No. 2) Limited, England Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
EP3880663A1 (en) * 2018-11-15 2021-09-22 Teva Pharmaceuticals International GmbH Solid state forms of daprodustat and process for preparation thereof

Also Published As

Publication number Publication date
WO2021255159A1 (en) 2021-12-23
EP4167967A1 (en) 2023-04-26
JP2023532223A (ja) 2023-07-27
JP7797425B2 (ja) 2026-01-13
US20230225977A1 (en) 2023-07-20
CN115697307A (zh) 2023-02-03
CA3180509A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
BR112016007479A2 (pt) regimes de dosagem de imunoconjugado de anti-folr1
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CR20120349A (es) Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
ECSP17077930A (es) Métodos y kits para tratar la depresión
MX2017014716A (es) Polipeptido de fusion anti-cancer.
AR061343A1 (es) Productos farmaceuticos uso de un antagonista de ccr5
ECSP12011735A (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112023024209A2 (pt) Composições que compreendem um agente terapêutico de redirecionamento de células t e um agente terapêutico anti-cd44
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
BR112014021602A2 (pt) uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
BR112014027047A2 (pt) nova formulação
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112019000837A2 (pt) células miméticas de célula b
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
BR112013001462B8 (pt) Composições

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements